JP2019519246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519246A5 JP2019519246A5 JP2018569009A JP2018569009A JP2019519246A5 JP 2019519246 A5 JP2019519246 A5 JP 2019519246A5 JP 2018569009 A JP2018569009 A JP 2018569009A JP 2018569009 A JP2018569009 A JP 2018569009A JP 2019519246 A5 JP2019519246 A5 JP 2019519246A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- virus
- composition
- cell population
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 25
- 238000000034 method Methods 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 102000004127 Cytokines Human genes 0.000 claims 6
- 108090000695 Cytokines Proteins 0.000 claims 6
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 4
- 108090000172 Interleukin-15 Proteins 0.000 claims 4
- 108010002586 Interleukin-7 Proteins 0.000 claims 4
- 238000009169 immunotherapy Methods 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 101710120600 Cancer/testis antigen 1 Proteins 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000000763 Survivin Human genes 0.000 claims 2
- 108010002687 Survivin Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 108010074108 interleukin-21 Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 101150059079 EBNA1 gene Proteins 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 claims 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 101150113776 LMP1 gene Proteins 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 241000907316 Zika virus Species 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- -1 pp65 Proteins 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022031731A JP2022066355A (ja) | 2016-06-28 | 2022-03-02 | 免疫療法向けのｔ細胞組成物 |
| JP2024083379A JP2024103547A (ja) | 2016-06-28 | 2024-05-22 | 免疫療法向けのｔ細胞組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355506P | 2016-06-28 | 2016-06-28 | |
| US201662355533P | 2016-06-28 | 2016-06-28 | |
| US201662355458P | 2016-06-28 | 2016-06-28 | |
| US62/355,458 | 2016-06-28 | ||
| US62/355,533 | 2016-06-28 | ||
| US62/355,506 | 2016-06-28 | ||
| PCT/US2017/039846 WO2018005712A1 (en) | 2016-06-28 | 2017-06-28 | T cell compositions for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031731A Division JP2022066355A (ja) | 2016-06-28 | 2022-03-02 | 免疫療法向けのｔ細胞組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519246A JP2019519246A (ja) | 2019-07-11 |
| JP2019519246A5 true JP2019519246A5 (https=) | 2020-08-06 |
| JP7034955B2 JP7034955B2 (ja) | 2022-03-14 |
Family
ID=60787739
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018569009A Active JP7034955B2 (ja) | 2016-06-28 | 2017-06-28 | 免疫療法向けのｔ細胞組成物 |
| JP2022031731A Pending JP2022066355A (ja) | 2016-06-28 | 2022-03-02 | 免疫療法向けのｔ細胞組成物 |
| JP2024083379A Pending JP2024103547A (ja) | 2016-06-28 | 2024-05-22 | 免疫療法向けのｔ細胞組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031731A Pending JP2022066355A (ja) | 2016-06-28 | 2022-03-02 | 免疫療法向けのｔ細胞組成物 |
| JP2024083379A Pending JP2024103547A (ja) | 2016-06-28 | 2024-05-22 | 免疫療法向けのｔ細胞組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200237819A1 (https=) |
| EP (1) | EP3487990A4 (https=) |
| JP (3) | JP7034955B2 (https=) |
| KR (1) | KR20190037243A (https=) |
| CN (1) | CN109715788A (https=) |
| AU (3) | AU2017290119A1 (https=) |
| CA (1) | CA3068387A1 (https=) |
| IL (1) | IL263896A (https=) |
| MX (1) | MX2019000180A (https=) |
| SG (1) | SG11201811745UA (https=) |
| WO (1) | WO2018005712A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102625832A (zh) | 2009-08-24 | 2012-08-01 | 贝勒医学院 | 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系 |
| ES2748652T3 (es) | 2012-02-09 | 2020-03-17 | Baylor College Medicine | Mezclas pep para generar CTL multivíricos con amplia especificidad |
| US20180072990A1 (en) * | 2015-03-20 | 2018-03-15 | Children's National Medical Center | Generating virus or other antigen-specific t cells from a naïve t cell population |
| HUE066460T2 (hu) | 2016-10-26 | 2024-08-28 | Iovance Biotherapeutics Inc | A kriokonzervált tumor infiltráló limfociták restimulációja |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| KR102618948B1 (ko) | 2016-11-17 | 2023-12-27 | 이오반스 바이오테라퓨틱스, 인크. | 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법 |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| CN110199017A (zh) | 2017-01-20 | 2019-09-03 | 国立大学法人京都大学 | CD8α+β+细胞毒性T细胞的制备方法 |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| TW201930340A (zh) * | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| EP3737743A1 (en) | 2018-01-08 | 2020-11-18 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JP7198602B2 (ja) * | 2018-07-11 | 2023-01-04 | カワサキモータース株式会社 | 自動二輪車 |
| EP3831936A4 (en) * | 2018-07-31 | 2022-04-13 | Thyas Co. Ltd. | METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS |
| AU2019314888A1 (en) * | 2018-07-31 | 2021-02-18 | Polybiocept Gmbh | Production and selection of tumor uber reactive immune cells (TURICs) |
| JP2021533759A (ja) * | 2018-08-10 | 2021-12-09 | ユーティレックス カンパニー リミテッド | 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法 |
| EP3834833A4 (en) * | 2018-08-10 | 2022-05-18 | Eutilex Co., Ltd. | CANCER ANTIGEN-SPECIFIC CYTOTOXIC T-CELLS |
| JP7632868B2 (ja) * | 2018-10-26 | 2025-02-19 | 国立大学法人信州大学 | 高効率な遺伝子改変細胞の作製方法 |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| WO2020092839A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| MY210603A (en) | 2018-11-05 | 2025-10-01 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| US12611427B2 (en) | 2018-11-05 | 2026-04-28 | Iovance Biotherapeutics, Inc. | Treatment of NSCLC patients refractory for anti-PD-1 antibody |
| WO2020102701A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Methods for the manufacture of th1/tc1 phenotype t cells |
| US20220064597A1 (en) * | 2018-12-18 | 2022-03-03 | Beth Israel Deaconess Medical Center, Inc. | Generation of organoid-primed T (opT) cells with memory phenotype |
| WO2020146434A2 (en) * | 2019-01-07 | 2020-07-16 | Children's National Medical Center | Ex vivo activated t-lymphocytic compositions and methods of using the same |
| JP7649244B2 (ja) * | 2019-02-14 | 2025-03-19 | リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル | 免疫細胞の効力をアッセイするための刺激剤の使用 |
| JP7668226B2 (ja) * | 2019-03-30 | 2025-04-24 | ビオンテック ユーエス インコーポレイテッド | Ｔ細胞組成物を調製するための組成物および方法、ならびにそれらの使用 |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| EP3976068A4 (en) * | 2019-05-31 | 2023-08-09 | Children's National Medical Center | CYTOKINE COCKTAILS FOR SELECTIVE T-LYMPHOCYTE SUBSET EXPANSION |
| WO2020263919A1 (en) * | 2019-06-24 | 2020-12-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes |
| JP7337373B2 (ja) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | 抗原特異的ｔ細胞の製造方法 |
| CN114615886A (zh) * | 2019-08-29 | 2022-06-10 | 得克萨斯大学体系董事会 | 细胞冷冻保存培养基 |
| US20230032934A1 (en) * | 2019-11-27 | 2023-02-02 | Myst Therapeutics, Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
| EP4081226A4 (en) * | 2019-12-23 | 2024-03-27 | Baylor College of Medicine | T CELL PERFORMANCE ASSAY AS A PROGNOSIS FACTOR FOR CLINICAL OUTCOME |
| US12378521B2 (en) | 2020-04-15 | 2025-08-05 | Amgen Inc. | Method for enhancing production of genetically engineered autologous T cells |
| US12241086B2 (en) | 2020-04-15 | 2025-03-04 | Amgen Inc. | Process for generating genetically engineered autologous T cells |
| JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
| WO2022115641A2 (en) * | 2020-11-25 | 2022-06-02 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| JP2024512029A (ja) | 2021-03-25 | 2024-03-18 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用 |
| CN113512529B (zh) * | 2021-07-21 | 2022-11-25 | 上海赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ab的制备方法 |
| CN113564116B (zh) * | 2021-07-21 | 2023-08-01 | 北京赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ce的制备方法 |
| CN113481157B (zh) * | 2021-07-21 | 2023-03-17 | 上海赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞的优化制备方法 |
| US20250130220A1 (en) * | 2021-09-08 | 2025-04-24 | KSQ Therapeutics, Inc. | Lymphocyte potency assay |
| EP4412628A1 (en) * | 2021-10-08 | 2024-08-14 | Baylor College of Medicine | Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy |
| JP2023064787A (ja) * | 2021-10-27 | 2023-05-12 | 国立大学法人京都大学 | Ｔ細胞の品質評価方法、および当該方法に用いる試薬 |
| US20250223552A1 (en) * | 2022-03-18 | 2025-07-10 | St. Jude Children's Research Hospital, Inc. | Method for preparing t cells for adoptive t cell therapy |
| JP2025512401A (ja) | 2022-04-15 | 2025-04-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス |
| KR102566680B1 (ko) * | 2022-09-28 | 2023-08-14 | (주)포에버엔케이 | 면역세포 및 자연살해세포 배양을 위한 신규한 이중배양 제조방법 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU765085B2 (en) * | 1998-05-11 | 2003-09-11 | Miltenyi Biotec Gmbh | Method of direct selection of antigen-specific T cells |
| WO2004015070A2 (en) | 2002-08-08 | 2004-02-19 | Baylor College Of Medicine | Isolation and identification of t cells |
| ES2532896T5 (es) | 2008-05-14 | 2018-03-20 | Immatics Biotechnologies Gmbh | Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan |
| CN102625832A (zh) | 2009-08-24 | 2012-08-01 | 贝勒医学院 | 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系 |
| US9114100B2 (en) * | 2010-05-17 | 2015-08-25 | Duke University | Methods of treatment using ex vivo expansion of cord blood T cells |
| AU2012258603A1 (en) * | 2011-05-26 | 2014-01-16 | Geneius Biotechnology, Inc. | Modulated immunodominance therapy |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| CN106687584B (zh) * | 2014-09-04 | 2021-08-13 | 干细胞技术公司 | 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物 |
| EP3234130B1 (en) * | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| HK1255161A1 (zh) * | 2015-07-15 | 2019-08-09 | Juno Therapeutics, Inc. | 用於过继性细胞治疗的工程细胞 |
-
2017
- 2017-06-28 MX MX2019000180A patent/MX2019000180A/es unknown
- 2017-06-28 JP JP2018569009A patent/JP7034955B2/ja active Active
- 2017-06-28 CA CA3068387A patent/CA3068387A1/en active Pending
- 2017-06-28 WO PCT/US2017/039846 patent/WO2018005712A1/en not_active Ceased
- 2017-06-28 US US16/312,023 patent/US20200237819A1/en not_active Abandoned
- 2017-06-28 CN CN201780053540.8A patent/CN109715788A/zh active Pending
- 2017-06-28 EP EP17821200.7A patent/EP3487990A4/en active Pending
- 2017-06-28 KR KR1020197002828A patent/KR20190037243A/ko not_active Ceased
- 2017-06-28 AU AU2017290119A patent/AU2017290119A1/en not_active Abandoned
- 2017-06-28 SG SG11201811745UA patent/SG11201811745UA/en unknown
-
2018
- 2018-12-23 IL IL263896A patent/IL263896A/en unknown
-
2022
- 2022-03-02 JP JP2022031731A patent/JP2022066355A/ja active Pending
- 2022-06-16 US US17/807,213 patent/US20230145991A1/en active Pending
-
2023
- 2023-10-26 AU AU2023254998A patent/AU2023254998A1/en not_active Abandoned
-
2024
- 2024-05-22 JP JP2024083379A patent/JP2024103547A/ja active Pending
-
2026
- 2026-03-24 AU AU2026202260A patent/AU2026202260A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519246A5 (https=) | ||
| Withers et al. | Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program | |
| JP7034955B2 (ja) | 免疫療法向けのｔ細胞組成物 | |
| Riddell et al. | The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells | |
| JP2023130355A (ja) | ナイーブｔ細胞集団からのウイルスまたは他の抗原に特異的なｔ細胞の生成 | |
| JP2014514927A5 (https=) | ||
| JP2019531722A5 (https=) | ||
| JP2014511704A5 (https=) | ||
| US10772914B1 (en) | EBV-specific immune cells | |
| Full et al. | T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor | |
| Liu et al. | CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals | |
| JP2019530449A (ja) | 幹細胞様メモリーｔ細胞の生成および養子免疫療法における使用 | |
| JP2021536260A5 (https=) | ||
| Stanhope et al. | Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine | |
| CN111529697A (zh) | 调节的免疫优势疗法 | |
| WO2021148547A1 (en) | Hbv specific tcr library and its use as personalised medicine | |
| JP2020506943A5 (https=) | ||
| Wang et al. | Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context | |
| Nowakowska et al. | T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus–transformed B cells | |
| Foster et al. | Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy | |
| Nolte et al. | Assessment and characterization of the cytolytic T lymphocyte response against Epstein–Barr virus in patients with non-Hodgkin’s lymphoma after autologous peripheral blood stem cell transplantation | |
| Kocher et al. | Quality of vaccination-induced T cell responses is conveyed by polyclonality and high, but not maximum, antigen receptor avidity | |
| Liu et al. | The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine | |
| Beloki et al. | Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor–mobilized donors | |
| Li et al. | Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy |